MOTS-c · Research brief

How to Inject MOTS-C Subq — Preparation to Post-Injection

Real Peptides Research TeamEditorial

Updated July 6, 202610 min read

42 WORDS

Short answer

Key takeaways

Reconstitute MOTS-C with bacteriostatic water injected slowly down the vial wall to prevent foam formation and peptide bond shearing. High-velocity injection is the most common cause of potency loss.
Refrigerate reconstituted MOTS-C at 2–8°C immediately after mixing and store for a maximum of 28 days. Any temperature excursion above 8°C initiates irreversible protein denaturation.
Use insulin syringes calibrated in mL (not unit markings) to draw the exact dose based on your reconstitution concentration. A 5mg vial in 2mL yields 2.5mg/mL, requiring 0.2mL per 0.5mg dose.
Rotate injection sites across the abdomen, anterior thighs, and dorsal upper arms with at least 1 inch spacing between sites. Repeated injections in the same location cause lipohypertrophy and reduce absorption.
Inject subcutaneously at a 45–90° angle into pinched tissue, advancing the needle fully before depressing the plunger. Partial insertion results in intradermal injection and localised irritation.
Monitor for injection site redness, swelling, or persistent induration lasting beyond 24 hours. These indicate either improper technique or contaminated solution requiring protocol review.

The most common error when learning to inject MOTS-C subq isn't the needle insertion. It's the reconstitution step that precedes it. A peptide mixed incorrectly loses potency before you ever draw the first dose, turning an effective mitochondrial compound into expensive saline. Temperature excursions during storage, air injection during reconstitution, and incorrect diluent volume each independently negate the peptide's bioavailability. Yet most first-time users focus exclusively on injection technique and ignore the preparation protocol entirely.

Our team has worked with researchers across hundreds of MOTS-C protocols. The gap between effective administration and wasted product comes down to three variables most guides skip: sterile reconstitution under controlled conditions, accurate dose measurement using insulin syringes calibrated to micrograms, and subcutaneous site rotation that prevents lipohypertrophy. The rest of this piece covers the exact step sequence to inject MOTS-C subq from vial receipt through post-injection storage, the preparation mistakes that destroy peptide integrity, and what to monitor during your first 72 hours.

How do you properly inject MOTS-C subq?

To inject MOTS-C subq, reconstitute the lyophilised peptide with bacteriostatic water at a 1:1 or 2:1 ratio (typically 2mg peptide to 2mL diluent), refrigerate the solution at 2–8°C, draw the prescribed dose using an insulin syringe, pinch subcutaneous tissue on the abdomen or thigh, insert the needle at a 45–90° angle, inject slowly over 5–10 seconds, and withdraw. The reconstituted peptide remains stable for 28 days under refrigeration.

Direct Context: Why MOTS-C Administration Differs from Standard Peptides

MOTS-C (mitochondrial open reading frame of the 12S rRNA-c) is a mitochondrial-derived peptide that regulates metabolic function, insulin sensitivity, and mitochondrial biogenesis. It is not a GLP-1 agonist, growth hormone secretagogue, or anabolic peptide. The administration technique mirrors other research peptides in mechanical execution but differs in reconstitution concentration: MOTS-C is typically dosed at 5–15mg per injection 2–3 times weekly, requiring higher peptide-to-diluent ratios than daily-use compounds. The short 16-amino-acid sequence also makes it more susceptible to degradation from temperature fluctuations and repeated freeze-thaw cycles than longer-chain peptides like BPC-157 or TB-500.

This article walks through the complete injection sequence. From vial storage temperature to post-injection site care. With specific attention to the reconstitution variables that preserve or destroy peptide integrity before the solution ever reaches the syringe. Researchers familiar with other subcutaneous peptides will recognise the mechanical technique; the differentiation lies in preparation protocol and stability considerations unique to mitochondrial peptides.

Step 1: Verify Storage Conditions and Gather Sterile Supplies Before Reconstitution

MOTS-C arrives as lyophilised (freeze-dried) powder stored at −20°C. Before reconstitution, confirm the vial has remained frozen during shipping. Condensation inside the vial or a clumped powder texture indicates temperature excursion that may have compromised the peptide structure. Allow the sealed vial to reach room temperature (20–25°C) for 10–15 minutes before opening. Injecting cold bacteriostatic water into a frozen vial creates thermal shock that denatures proteins.

Gather these supplies on a clean, non-porous surface wiped with 70% isopropyl alcohol: the MOTS-C vial, bacteriostatic water (0.9% benzyl alcohol), alcohol prep pads, insulin syringes (typically 0.3mL or 0.5mL with 29G–31G needles), and a sharps disposal container. Our experience working with peptide researchers shows that using non-bacteriostatic (sterile) water reduces reconstituted shelf life to 72 hours versus 28 days with bacteriostatic solution. The benzyl alcohol preservative prevents bacterial growth during repeated punctures of the rubber stopper.

Calculate your target concentration before opening the vial. Example: a 5mg MOTS-C vial reconstituted with 2mL bacteriostatic water yields 2.5mg/mL concentration. If your dose is 10mg, you would draw 4mL total. Which exceeds single-vial capacity and requires splitting across two vials. Adjust diluent volume to match your planned injection schedule: researchers injecting 5mg twice weekly from a 10mg vial typically reconstitute with 2mL, yielding four 0.5mL doses.

Step 2: Reconstitute the Peptide Using Sterile Technique and Controlled Injection Speed

Remove the plastic cap from the MOTS-C vial and swab the rubber stopper with an alcohol prep pad. Allow 10 seconds of air-dry time before puncture. Draw your calculated volume of bacteriostatic water into a syringe (e.g., 2mL for a 5mg vial). Insert the needle through the rubber stopper at a slight angle to prevent coring (tearing rubber fragments into the solution), then angle the needle so the tip contacts the inner glass wall. Not the powder at the vial bottom.

Inject the bacteriostatic water slowly down the vial wall, allowing it to gently dissolve the peptide powder rather than striking it directly with liquid force. High-velocity injection creates foam and mechanical shearing that breaks peptide bonds. This is the single most common preparation error. The process should take 15–20 seconds for 2mL. Do NOT shake the vial. Gently swirl or roll the vial between your palms until the powder fully dissolves into a clear solution. Visible particles, cloudiness, or persistent undissolved powder indicate contamination or denaturation. Discard the vial.

Withdraw the syringe and immediately transfer the reconstituted vial to refrigeration at 2–8°C. Light exposure degrades MOTS-C. Store the vial in its original box or wrap it in aluminium foil. The reconstituted solution remains stable for 28 days under continuous refrigeration. Any temperature excursion above 8°C. Even for 30 minutes. Initiates irreversible protein denaturation. At Real Peptides, we've seen researchers lose entire vials to single-day room-temperature storage during protocol setup.

Step 3: Draw the Prescribed Dose Using Insulin Syringe Calibration and Air Displacement Prevention

Remove the reconstituted vial from refrigeration and allow it to reach room temperature for 5 minutes. Injecting cold solution subcutaneously increases discomfort and slows absorption. Swab the rubber stopper with a fresh alcohol prep pad. Draw air into an insulin syringe equal to your target dose volume (e.g., 0.5mL for a 5mg dose from 2.5mg/mL concentration). Insert the needle through the stopper, inject the air into the vial headspace. This prevents vacuum formation that makes solution withdrawal difficult. Then invert the vial and slowly pull the plunger to draw the solution.

Hold the syringe at eye level with the needle pointing upward. Tap the barrel gently to dislodge air bubbles, then push the plunger until a small droplet appears at the needle tip. This confirms no air remains in the syringe. Air bubbles in subcutaneous injections are not dangerous (they dissipate into tissue harmlessly), but they displace solution volume and result in underdosing. If your target is 0.5mL and 0.05mL consists of air, you've administered only 90% of your intended dose.

Insulin syringes use unit markings that correspond to insulin concentration (100 units per mL for U-100 insulin). For peptide dosing, ignore unit markings and use the mL graduations on the opposite barrel side. Example: 0.5mL = 50 units on a U-100 syringe. Double-check your drawn volume against your calculated dose before proceeding. Reconstitution math errors are the second most common failure point after improper mixing technique.

MOTS-C Injection: Technique Comparison

Administration Route	Needle Gauge	Injection Depth	Typical Sites	Absorption Speed	Professional Assessment
Subcutaneous (subq)	29G–31G	4–6mm into fat layer	Abdomen, anterior thigh, dorsal upper arm	Moderate. Peaks 30–90 min	Standard route for MOTS-C; consistent bioavailability, minimal discomfort, easy self-administration
Intramuscular (IM)	23G–25G	1–1.5 inches into muscle	Vastus lateralis, gluteus, deltoid	Faster. Peaks 15–45 min	Not typically used for MOTS-C; no documented bioavailability advantage and higher injection site pain
Intravenous (IV)	20G–22G	Direct venous access	Antecubital fossa, hand veins	Immediate. Systemic within seconds	Requires clinical setting; bypasses first-pass metabolism but offers no therapeutic benefit for MOTS-C's mechanism

What If: MOTS-C Injection Scenarios

What If the Reconstituted Solution Appears Cloudy or Contains Particles?

Discard the vial immediately. Cloudiness or visible particles indicate bacterial contamination, improper reconstitution, or peptide aggregation. Clear solution is the only acceptable appearance for reconstituted MOTS-C. Attempting to filter the solution through a syringe filter introduces additional contamination risk and does not restore peptide integrity if aggregation has already occurred. Cloudiness within 24 hours of reconstitution most commonly results from injecting bacteriostatic water too rapidly during mixing or using non-sterile diluent.

What If You Experience a Burning Sensation During Injection?

Slow your injection speed. Burning typically indicates the solution is being injected too quickly, overwhelming the subcutaneous space and causing localised pressure. The injection should take 5–10 seconds for 0.5mL volume. If burning persists despite slow injection, confirm the solution reached room temperature before use. Injecting cold peptide directly from refrigeration causes significant discomfort. Persistent burning accompanied by immediate redness suggests the injection penetrated too shallowly (intradermal rather than subcutaneous) or the needle contacted a nerve.

What If You Miss Your Injection Window by 12–24 Hours?

Administer the dose as soon as you remember if fewer than 24 hours have passed since your scheduled time, then continue your regular schedule. MOTS-C has no established half-life in current literature, but mitochondrial peptides demonstrate sustained effects beyond their plasma clearance. Missing a single dose by one day does not negate accumulated metabolic adaptations. If more than 48 hours have passed, skip the missed dose entirely and resume on your next scheduled injection day. Do not double-dose to compensate.

What If the Injection Site Develops a Firm Lump That Persists Beyond 48 Hours?

A palpable subcutaneous nodule lasting more than 48 hours indicates either lipohypertrophy from repeated injections in the same site or an immune response to the benzyl alcohol preservative in bacteriostatic water. Rotate to a new anatomical region (if you've been using only abdomen, switch to thigh) and allow the affected site to rest for 2–3 weeks. If new lumps form at fresh sites, consider switching to sterile water for reconstitution. Approximately 2–3% of users demonstrate sensitivity to benzyl alcohol, requiring injection within 72 hours of mixing when using preservative-free diluent.

The Unvarnished Truth About MOTS-C Self-Administration

Here's the honest answer: the overwhelming majority of peptide administration errors occur during reconstitution and storage. Not during the injection itself. Researchers who approach this as 'just add water and inject' consistently produce solutions with degraded potency, then attribute lack of results to the peptide rather than preparation failure. The mechanical act of injecting subcutaneously is trivial by comparison. Insert needle, depress plunger, withdraw. The expertise requirement lies in sterile technique, accurate dose calculation, and temperature-controlled storage across the 28-day use window.

If you reconstitute peptides on your kitchen counter without alcohol-wiping the work surface, inject bacteriostatic water rapidly into the vial, or store reconstituted solution in a refrigerator that cycles above 8°C during defrost. You are compromising peptide integrity before the first injection. Those practices are not 'close enough'. They represent the difference between administering active compound and injecting inert amino acid fragments. MOTS-C is a 16-amino-acid sequence without complex tertiary structure, which makes it more forgiving than folded proteins like insulin, but it is not immune to mechanical shearing, thermal denaturation, or bacterial contamination.

The reconstitution step determines whether you inject MOTS-C subq or inject degraded solution that produces no measurable effect. Treat preparation protocol as seriously as injection technique. One cannot succeed without the other.

Subcutaneous injection of MOTS-C follows the same mechanical protocol as other research peptides, but the compound's mitochondrial origin and relatively short amino acid sequence introduce preparation variables that differ from longer-chain peptides or growth factors. Researchers who master sterile reconstitution, accurate dose measurement, and temperature-controlled storage consistently report reproducible results; those who shortcut preparation protocol see inconsistent outcomes regardless of injection technique proficiency. The peptide's mechanism. Upregulation of mitochondrial biogenesis and AMPK pathway activation. Requires intact amino acid sequencing that survives from vial manufacturing through subcutaneous delivery.

Storing lyophilised MOTS-C below −20°C before reconstitution and maintaining reconstituted solution at 2–8°C afterward are non-negotiable baseline requirements. Rotating injection sites across anatomically distinct regions prevents lipohypertrophy that reduces local absorption. Using insulin syringes with mL graduations rather than unit markings eliminates dose calculation errors. Each of these variables independently affects bioavailability. Together, they determine whether the peptide you inject MOTS-C subq retains the molecular structure required for mitochondrial receptor binding. The technical execution is straightforward; the discipline required to maintain sterile conditions and controlled temperatures across weeks of repeated dosing is where most protocols succeed or fail.

All compounds discussed on this page are sold for research use only and are not for human consumption.

References

Peer-reviewed sources on MOTS-c indexed in PubMed, listed for research context. Real Peptides supplies MOTS-c for laboratory research use only.

MOTS-c improves intrinsic muscle mitochondrial bioenergetic health and efficiency in a PGC-1α/AMPK-dependent manner. Free radical biology & medicine, 2026. PMID 41520850. doi:10.1016/j.freeradbiomed.2026.01.002
Humanin and MOTS-c Attenuate Atrial Fibrillation by Suppressing Fibrosis and Mitochondrial Dysfunction. Biomedicines, 2026. PMID 42193373. doi:10.3390/biomedicines14051048
MOTS-c, a mitochondrial-derived peptide, ameliorates lysosomal membrane permeability and improves survival of soft tissue transplantation. Autophagy, 2026. PMID 42153537. doi:10.1080/15548627.2026.2677180
Mitochondrial-derived peptide MOTS-c targets SLC7A11 to preserve spermatogenesis by suppressing ferroptosis. Free radical biology & medicine, 2026. PMID 41933740. doi:10.1016/j.freeradbiomed.2026.03.074
MOTS-c attenuates cardiac dysfunction following high altitude exposure by promoting mitophagy. Free radical biology & medicine, 2026. PMID 41654147. doi:10.1016/j.freeradbiomed.2026.01.064
Mitochondrial-encoded peptide MOTS-c prevents pancreatic islet cell senescence to delay diabetes. Experimental & molecular medicine, 2025. PMID 40855115. doi:10.1038/s12276-025-01521-1
MOTS-c attenuates mitochondrial dysfunction induces pyroptosis and cartilage degradation in osteoarthritis via an Nrf2-Dependent Mechanism. Free radical biology & medicine, 2025. PMID 41043625. doi:10.1016/j.freeradbiomed.2025.09.056
MOTS-c Promotes Glycolysis via AMPK-HIF-1α-PFKFB3 Pathway to Ameliorate Cardiopulmonary Bypass-induced Lung Injury. American journal of respiratory cell and molecular biology, 2025. PMID 40035775. doi:10.1165/rcmb.2024-0533OC

Build a pack

Researching more than one compound?

Build a multi-vial pack and the discount applies automatically as you add doses.

Start a pack

Questions

Reconstituted MOTS-C remains stable for 28 days when stored continuously at 2–8°C in bacteriostatic water. The benzyl alcohol preservative in bacteriostatic water prevents bacterial growth during this window despite repeated needle punctures through the rubber stopper. If reconstituted with sterile water instead, stability drops to 72 hours maximum — sterile water lacks preservative, making the solution vulnerable to contamination after the first puncture.

Yes, MOTS-C can be injected intramuscularly, but there is no documented bioavailability advantage and IM injection causes significantly more discomfort due to larger needle gauge requirements and deeper tissue penetration. Subcutaneous administration delivers consistent absorption with minimal injection site pain, making it the standard route for this peptide. IM injection is typically reserved for compounds where rapid systemic delivery provides therapeutic benefit — a characteristic MOTS-C does not demonstrate.

Peptides left at room temperature for more than 4–6 hours undergo progressive protein denaturation that reduces bioavailability — the longer the exposure, the greater the potency loss. An overnight excursion (8–12 hours at 20–25°C) likely renders the solution partially or fully inactive. Discard any reconstituted MOTS-C exposed to room temperature overnight and prepare a fresh vial — injecting degraded peptide wastes the dose without delivering therapeutic effect.

Divide your target dose (in mg) by the concentration you created during reconstitution (in mg/mL) to get injection volume in mL. Example: if you reconstituted a 10mg vial with 2mL bacteriostatic water, concentration is 5mg/mL. To inject 5mg MOTS-C subq, you would draw 1mL (5mg ÷ 5mg/mL = 1mL). Always double-check your math before drawing the dose — reconstitution calculation errors are the second most common cause of incorrect dosing after improper vial mixing.

Yes, minor bleeding from the puncture site is common and harmless — it indicates the needle passed through a small capillary during insertion. Apply gentle pressure with a sterile gauze pad or alcohol wipe for 10–20 seconds until bleeding stops. Persistent bleeding beyond 60 seconds or bruising larger than 1cm in diameter suggests you may have used excessive force during insertion or withdrew the needle too quickly — both errors increase capillary trauma.

Both 29G and 31G needles are appropriate for subcutaneous MOTS-C injection — the difference lies in needle diameter and associated comfort. A 31G needle (0.25mm diameter) is thinner and causes less sensation during insertion but requires slightly more pressure to depress the plunger due to narrower bore. A 29G needle (0.33mm diameter) punctures more easily but produces marginally more insertion discomfort. For viscous solutions or users with reduced hand strength, 29G offers easier plunger depression; for pain-sensitive individuals, 31G minimises sensation.

No — do not massage the injection site after subcutaneous peptide administration. Massaging accelerates absorption by dispersing the solution into surrounding tissue and increasing local blood flow, which can cause rapid systemic delivery that may increase side effects. Allow the peptide to absorb naturally over 30–90 minutes without manipulation. Gentle pressure immediately after needle withdrawal to stop minor bleeding is acceptable, but avoid rubbing or kneading the area.

Yes, insulin syringes are designed as single-use, integrated units where the needle is permanently attached to the syringe barrel — you draw and inject with the same needle. The needle dulls slightly when puncturing the rubber stopper during solution withdrawal, but this does not meaningfully affect subcutaneous injection comfort with 29G–31G needles. Never reuse needles across multiple injections — each injection requires a fresh sterile syringe to prevent contamination and infection risk.

Research protocols most commonly use 5–15mg MOTS-C administered 2–3 times per week, though optimal frequency remains under investigation. The peptide's sustained metabolic effects suggest that daily dosing is unnecessary, and some protocols space injections 3–4 days apart. Frequency should align with individual protocol design rather than a universal standard — researchers typically start with twice-weekly administration and adjust based on observed metabolic markers.

Rotate injection sites systematically across anatomically distinct regions — use a different quadrant of the abdomen each injection, or alternate between abdomen, anterior thigh, and dorsal upper arm. Maintain at least 1 inch (2.5cm) spacing between injection points and avoid returning to the same site within 7–10 days. Lipohypertrophy develops from repeated trauma to the same subcutaneous tissue, creating fibrous nodules that reduce peptide absorption and increase injection discomfort.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA